Pancreatic Cancer Research

Journal articleAm J Case Rep2020

Irinotecan-Associated Dysarthria in Patients with Pancreatic Cancer: A Single Site Experience.

Journal
Am J Case Rep
Published
28 June 2020
Citations
1
Type
Article
License
cc by-nc-nd

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract cc by-nc-nd

BACKGROUND Irinotecan, a topoisomerase I inhibitor, is a cytotoxic chemotherapeutic agent used to treat multiple malignancies, including those of colorectal, pancreatic, cervical, esophageal, gastric, and lung origin. Dysarthria, a state of difficult or unclear articulation of speech, has been reported as a rare side effect of irinotecan through multiple case reports and case series, but with limited published data aimed at understanding the underlying mechanism and effective management strategies. … Excerpt only: this text is the publisher’s. Read it in full at the source.